Answers are grounded in this paper and cite their sources.
Polycythemia vera (PV) is a human clonal hematological disorder. The molecular etiology of the disease has not been identified. PV hematopoietic progenitor cells exhibit hypersensitivity to growth factors and cytokines, suggesting possible abnormalities in protein-tyrosine kinases and phosphatases. By sequencing the entire coding regions of cDNAs of candidate enzymes, we identified a G:C→ T:A point mutation of the JAK2 tyrosine kinase in 20 of 24 PV blood samples but none in 12 normal samples. The mutation has varying degrees of heterozygosity and is apparently acquired. It changes conserved Val617 to Phe in the pseudokinase domain of JAK2 that is known to have an inhibitory role. The mutant JAK2 has enhanced kinase activity, and when overexpressed together with the erythropoietin receptor in cells, it caused hyperactivation of erythropoietin-induced cell signaling. This gain-of-function mutation of JAK may explain the hypersensitivity of PV progenitor cells to growth factors and cytokines. Our study thus defines a molecular defect of PV. Polycythemia vera (PV) is a human clonal hematological disorder. The molecular etiology of the disease has not been identified. PV hematopoietic progenitor cells exhibit hypersensitivity to growth factors and cytokines, suggesting possible abnormalities in protein-tyrosine kinases and phosphatases. By sequencing the entire coding regions of cDNAs of candidate enzymes, we identified a G:C→ T:A point mutation of the JAK2 tyrosine kinase in 20 of 24 PV blood samples but none in 12 normal samples. The mutation has varying degrees of heterozygosity and is apparently acquired. It changes conserved Val617 to Phe in the pseudokinase domain of JAK2 that is known to have an inhibitory role. The mutant JAK2 has enhanced kinase activity, and when overexpressed together with the erythropoietin receptor in cells, it caused hyperactivation of erythropoietin-induced cell signaling. This gain-of-function mutation of JAK may explain the hypersensitivity of PV progenitor cells to growth factors and cytokines. Our study thus defines a molecular defect of PV. Polycythemia vera (PV) 1The abbreviations used are: PV, polycythemia vera; PTK, protein-tyrosine kinase; PTP, protein-tyrosine phosphatase; EPO, erythropoietin; EPOR, erythropoietin receptor; GST, glutathione S-transferase; STAT, signal transducers and activators of transcription; ERK, extracellular signal-regulated kinase; JAK, Janus kinase; JH, JAK homology; SH, Src homology; IR, inhibitory region; IL, interleukin. 1The abbreviations used are: PV, polycythemia vera; PTK, protein-tyrosine kinase; PTP, protein-tyrosine phosphatase; EPO, erythropoietin; EPOR, erythropoietin receptor; GST, glutathione S-transferase; STAT, signal transducers and activators of transcription; ERK, extracellular signal-regulated kinase; JAK, Janus kinase; JH, JAK homology; SH, Src homology; IR, inhibitory region; IL, interleukin. is a clonal myeloproliferative disorder characterized by increased production of red cells, granulocytes, and platelets (1Green A.R. Lancet. 1996; 347: 844-845Abstract PubMed Scopus (20) Google Scholar, 2Prchal J.F. Prchal J.T. Curr. Opin. Hematol. 1999; 6: 100-109Crossref PubMed Scopus (45) Google Scholar, 3Spivak J.L. Blood. 2002; 100: 4272-4290Crossref PubMed Scopus (369) Google Scholar). It mainly affects people between 40 and 60 years of age with an annual incidence of about 14 per million in the population. Thus far there is no effective cure for the disease. Phlebotomy is the mainstay of treatment for the disease, and hydroxyurea, interferon-α, and anagrelide drug therapies and 32P radiation have been used J.L. Blood. 2002; 100: 4272-4290Crossref PubMed Scopus (369) Google Scholar). The is the disease is is with in the molecular etiology of PV of PV is that hematopoietic in to growth factors and (1Green A.R. Lancet. 1996; 347: 844-845Abstract PubMed Scopus (20) Google Scholar, 2Prchal J.F. Prchal J.T. Curr. Opin. Hematol. 1999; 6: 100-109Crossref PubMed Scopus (45) Google Scholar, 3Spivak J.L. Blood. 2002; 100: 4272-4290Crossref PubMed Scopus (369) Google Scholar). the of for the growth factors and the of cells suggesting a defect in a in is a for cell growth and and is by of protein-tyrosine kinases and 100: PubMed Scopus Google Scholar). of have and normal and of the human to the human there about and 2002; PubMed Scopus Google Scholar, PubMed Scopus Google Scholar, PubMed Scopus Google Scholar). mutation of and have been in human a that and in human of of mutation in and of has a mutation in PubMed Scopus Google Scholar, PubMed Scopus Google Scholar). It is that of and may a of of we that PV progenitor cells a that to Blood. PubMed Google Scholar, Blood. PubMed Scopus Google Scholar). is caused by of the a mutation in suggesting that is not the of the disease. the and and the of PV hematopoietic progenitor cells, we have a sequencing of a of candidate and we the of a JAK2 mutation in a of the PV samples. have the JAK2 mutant has a gain-of-function JAK2 and the erythropoietin receptor and of and blood samples and PV the for of the PV the for PV J.L. Blood. 2002; 100: 4272-4290Crossref PubMed Scopus (369) Google Scholar). The blood samples for of cells and for of in a of 20 cells by the cells Blood. PubMed Google and blood cells and cells by the and by cDNAs by of with of the JAK2 the used and for and and for of the JAK2 the and and 14 of the JAK2 with The and the the a for JAK kinase we a a to the of This of JAK2 the and The cells by JAK2 and the mutant the for in with the cells in a and a The JAK2 and the cell by The kinase JAK2 and The to for 20 and by of the of by with an of JAK2 and with and cells with and in the of the 40 the cells for and with 40 for The by the cells with and the cells of by and to The with that by the enhanced with of a JAK2 in we that PV caused by of the to the entire coding regions of a of and known in we and the identified in cells Blood. PubMed Scopus Google Scholar). we of the JAK, and growth receptor blood cells and of cDNAs by with to the and of the coding regions of candidate and samples that to in the with a of caused by and sequencing of the point and of and a point mutation of JAK2 in the of PV samples The JAK2 mutation is a G:C→ T:A of Val617 by the we of JAK2 in 20 of 24 samples but not in 12 normal samples the mutation with varying of the mutant JAK2 in the the mutant a of the in in in of the to the The mutation is apparently not to progenitor cells, no in the of mutant JAK2 with cells not the of PV. the point mutation in the of the JAK2 it not the of the of and mutant JAK2 the of the and mutant JAK2 in the samples. the of JAK2 the The mutation point is 14 of the JAK2 is in to a of the and 14 with an in mutation of JAK2 the to mutation with in the to of the mutant the samples. samples that of the JAK2 mutant in the with cDNAs mutant JAK2 with in of is in the mutation of JAK2 in PV in This is not hematopoietic cells and of JAK2 by the mutant cells, the mutant have an to and thus to to the in the the degrees of mutation with cDNAs and that the of JAK2 in PV not but in hematopoietic progenitor of the JAK2 of JAK JAK PubMed Scopus Google Scholar, 6: Scholar). Our of the by the the of in JAK2 The tyrosine kinase domain and pseudokinase domain to the and identified a domain that of the but the domain of JAK2 is not The the domain known the known to PubMed Google Scholar). of the of kinases of 12 with conserved PubMed Scopus Google Scholar, Scholar). The mutation point in of the pseudokinase domain in the The pseudokinase domain has the of but has no that it of the kinase The pseudokinase domain JAK2 by the of the kinase domain but not the inhibitory and have been in the pseudokinase domain PubMed Scopus Google Scholar). Val617 is to the and it is conserved in JAK2 of to It is conserved in human and but is by in that the of by Phe in JAK2 This may the inhibitory of the pseudokinase domain and thus of the kinase have that of the pseudokinase domain to hyperactivation of the with of kinase domain and Blood. PubMed Google Scholar). the of PV disease, it is that may a gain-of-function mutant and have increased kinase of the JAK2 is a of JAK2 together with the of the JAK in the the mutation in PV and of of the gain-of-function of we the tyrosine kinase of JAK2 and the mutant the and mutant in cells by the The cell by to the we used a the of JAK2 the The in that the by a JAK2 and a of that the mutation the kinase of has enhanced tyrosine kinase JAK2 and cells with with a in the of by and the of and by and a gain-of-function in cells, we with JAK2 in The cells with and of by of in a of and the of in the of that hyperactivation of signal by EPO, is for the growth of PV progenitor cells and the hypersensitivity of cells to growth factors and hyperactivation of cell signaling. cells with and JAK2 with 40 for and to with the that the of and not by the cell not the we identified an mutation of JAK2 in of PV samples that we This mutation of a by in the pseudokinase domain of JAK2 that has an inhibitory role. gain-of-function Our study by the mutant that the mutant has enhanced kinase and hyperactivation of signal of thus a molecular defect of the PV disease. This have in the and treatment of PV disease. has that tyrosine kinases for drug JAK2 thus a for to is a in by of the EPOR, the receptor and the receptor and the receptor 2002; PubMed Scopus Google Scholar, PubMed Scopus Google Scholar). JAK2 an of to a in PubMed Scopus Google Scholar, PubMed Scopus Google Scholar). This is to in and PubMed Scopus Google that JAK2 has for signal by growth factors and in growth in is Blood. PubMed Google Scholar). EPOR, not kinase activity, but it is with the of to JAK2 and in of and Blood. PubMed Google Scholar). and of progenitor cells the of PV progenitor cells the to in the of (1Green A.R. Lancet. 1996; 347: 844-845Abstract PubMed Scopus (20) Google Scholar, 2Prchal J.F. Prchal J.T. Curr. Opin. Hematol. 1999; 6: 100-109Crossref PubMed Scopus (45) Google Scholar, 3Spivak J.L. Blood. 2002; 100: 4272-4290Crossref PubMed Scopus (369) Google Scholar). have no in in PV cells, suggesting hyperactivation in it is not that we gain-of-function mutation of JAK2 in PV. a possible of JAK2 in PV. The JAK2 is to of of PV and in of PV A.R. PubMed Scopus Google Scholar). we mutation of JAK2 Val617 in 20 of 24 samples a JAK2 mutation of the a JAK have a domain with a kinase domain to a pseudokinase domain PubMed Scopus Google Scholar, 6: Scholar). The domain conserved in The of the in is by the conserved in the in is by in The of the pseudokinase domain has been the pseudokinase domain a by the kinase of The mutation the of in of the pseudokinase may changes and the inhibitory This to the kinase is a clonal disorder and the defect is to the progenitor The hypersensitivity of PV progenitor cells to growth and the growth of of progenitor cells in the of growth factors hyperactivation of an study that PV have Hematol. PubMed Scopus Google and a study increased of in cells PV Hematol. PubMed Scopus Google Scholar). a signal of EPOR, enhanced JAK2 to mutation hyperactivation of cell By JAK2 with in a cell study has that the JAK2 mutant of signal by the JAK2 mutant in hematopoietic progenitor cells normal blood by Blood. PubMed Scopus Google Scholar). to a the growth and of cells in not possible is that gain-of-function mutation of JAK2 not to This that abnormalities of may with PV. have been in A.R. Lancet. PubMed Scopus Google Scholar, PubMed Scopus Google Scholar, J.L. PubMed Scopus Google Scholar, PubMed Scopus Google Scholar). Polycythemia vera (PV) 1The abbreviations used are: PV, polycythemia vera; PTK, protein-tyrosine kinase; PTP, protein-tyrosine phosphatase; EPO, erythropoietin; EPOR, erythropoietin receptor; GST, glutathione S-transferase; STAT, signal transducers and activators of transcription; ERK, extracellular signal-regulated kinase; JAK, Janus kinase; JH, JAK homology; SH, Src homology; IR, inhibitory region; IL, interleukin. 1The abbreviations used are: PV, polycythemia vera; PTK, protein-tyrosine kinase; PTP, protein-tyrosine phosphatase; EPO, erythropoietin; EPOR, erythropoietin receptor; GST, glutathione S-transferase; STAT, signal transducers and activators of transcription; ERK, extracellular signal-regulated kinase; JAK, Janus kinase; JH, JAK homology; SH, Src homology; IR, inhibitory region; IL, interleukin. is a clonal myeloproliferative disorder characterized by increased production of red cells, granulocytes, and platelets (1Green A.R. Lancet. 1996; 347: 844-845Abstract PubMed Scopus (20) Google Scholar, 2Prchal J.F. Prchal J.T. Curr. Opin. Hematol. 1999; 6: 100-109Crossref PubMed Scopus (45) Google Scholar, 3Spivak J.L. Blood. 2002; 100: 4272-4290Crossref PubMed Scopus (369) Google Scholar). It mainly affects people between 40 and 60 years of age with an annual incidence of about 14 per million in the population. Thus far there is no effective cure for the disease. Phlebotomy is the mainstay of treatment for the disease, and hydroxyurea, interferon-α, and anagrelide drug therapies and 32P radiation have been used J.L. Blood. 2002; 100: 4272-4290Crossref PubMed Scopus (369) Google Scholar). The is the disease is is with in the molecular etiology of PV of PV is that hematopoietic in to growth factors and (1Green A.R. Lancet. 1996; 347: 844-845Abstract PubMed Scopus (20) Google Scholar, 2Prchal J.F. Prchal J.T. Curr. Opin. Hematol. 1999; 6: 100-109Crossref PubMed Scopus (45) Google Scholar, 3Spivak J.L. Blood. 2002; 100: 4272-4290Crossref PubMed Scopus (369) Google Scholar). the of for the growth factors and the of cells suggesting a defect in a in is a for cell growth and and is by of protein-tyrosine kinases and 100: PubMed Scopus Google Scholar). of have and normal and of the human to the human there about and 2002; PubMed Scopus Google Scholar, PubMed Scopus Google Scholar, PubMed Scopus Google Scholar). mutation of and have been in human a that and in human of of mutation in and of has a mutation in PubMed Scopus Google Scholar, PubMed Scopus Google Scholar). It is that of and may a of of PV. we that PV progenitor cells a that to Blood. PubMed Google Scholar, Blood. PubMed Scopus Google Scholar). is caused by of the a mutation in suggesting that is not the of the disease. the and and the of PV hematopoietic progenitor cells, we have a sequencing of a of candidate and we the of a JAK2 mutation in a of the PV samples. have the JAK2 mutant has a gain-of-function JAK2 and the erythropoietin receptor and of and blood samples and PV the for of the PV the for PV J.L. Blood. 2002; 100: 4272-4290Crossref PubMed Scopus (369) Google Scholar). The blood samples for of cells and for of in a of 20 cells by the cells Blood. PubMed Google and blood cells and cells by the and by cDNAs by of with of the JAK2 the used and for and and for of the JAK2 the and and 14 of the JAK2 with The and the the a for JAK kinase we a a to the of This of JAK2 the and The cells by JAK2 and the mutant the for in with the cells in a and a The JAK2 and the cell by The kinase JAK2 and The to for 20 and by of the of by with an of JAK2 and with and cells with and in the of the 40 the cells for and with 40 for The by the cells with and the cells of by and to The with that by the enhanced with JAK2 and the erythropoietin receptor and of and blood samples and PV the for of the PV the for PV J.L. Blood. 2002; 100: 4272-4290Crossref PubMed Scopus (369) Google Scholar). The blood samples for of cells and for of in a of 20 cells by the cells Blood. PubMed Google Scholar). and blood cells and cells by the and by cDNAs by of with of the JAK2 the used and for and and for of the JAK2 the and and 14 of the JAK2 with The and the the JAK2 a for JAK kinase we a a to the of This of JAK2 the and The cells by JAK2 and the mutant the for in with the cells in a and a The JAK2 and the cell by The kinase JAK2 and The to for 20 and by of the of by with an of JAK2 and with and cells with and in the of the 40 the cells for and with 40 for The by the cells with and the cells of by and to The with that by the enhanced with of a JAK2 in we that PV caused by of the to the entire coding regions of a of and known in we and the identified in cells Blood. PubMed Scopus Google Scholar). we of the JAK, and growth receptor blood cells and of cDNAs by with to the and of the coding regions of candidate and samples that to in the with a of caused by and sequencing of the point and of and a point mutation of JAK2 in the of PV samples The JAK2 mutation is a G:C→ T:A of Val617 by the we of JAK2 in 20 of 24 samples but not in 12 normal samples the mutation with varying of the mutant JAK2 in the the mutant a of the in in in of the to the The mutation is apparently not to progenitor cells, no in the of mutant JAK2 with cells not the of PV. the point mutation in the of the JAK2 it not the of the of and mutant JAK2 the of the and mutant JAK2 in the samples. the of JAK2 the The mutation point is 14 of the JAK2 is in to a of the and 14 with an in mutation of JAK2 the to mutation with in the to of the mutant the samples. samples that of the JAK2 mutant in the with cDNAs mutant JAK2 with in of is in the mutation of JAK2 in PV in This is not hematopoietic cells and of JAK2 by the mutant cells, the mutant have an to and thus to to the in the the degrees of mutation with cDNAs and that the of JAK2 in PV not but in hematopoietic progenitor of the JAK2 of JAK JAK PubMed Scopus Google Scholar, 6: Scholar). Our of the by the the of in JAK2 The tyrosine kinase domain and pseudokinase domain to the and identified a domain that of the but the domain of JAK2 is not The the domain known the known to PubMed Google Scholar). of the of kinases of 12 with conserved PubMed Scopus Google Scholar, Scholar). The mutation point in of the pseudokinase domain in the The pseudokinase domain has the of but has no that it of the kinase The pseudokinase domain JAK2 by the of the kinase domain but not the inhibitory and have been in the pseudokinase domain PubMed Scopus Google Scholar). Val617 is to the and it is conserved in JAK2 of to It is conserved in human and but is by in that the of by Phe in JAK2 This may the inhibitory of the pseudokinase domain and thus of the kinase have that of the pseudokinase domain to hyperactivation of the with of kinase domain and Blood. PubMed Google Scholar). the of PV disease, it is that may a gain-of-function mutant and have increased kinase and of of the gain-of-function of we the tyrosine kinase of JAK2 and the mutant the and mutant in cells by the The cell by to the we used a the of JAK2 the The in that the by a JAK2 and a of that the mutation the kinase of has enhanced tyrosine kinase JAK2 and cells with with a in the of by and the of and by and a gain-of-function in cells, we with JAK2 in The cells with and of by of in a of and the of in the of that hyperactivation of signal by EPO, is for the growth of PV progenitor cells and the hypersensitivity of cells to growth factors and hyperactivation of cell signaling. cells with and JAK2 with 40 for and to with the that the of and not by the cell not of a JAK2 in we that PV caused by of the to the entire coding regions of a of and known in we and the identified in cells Blood. PubMed Scopus Google Scholar). we of the JAK, and growth receptor blood cells and of cDNAs by with to the and of the coding regions of candidate and samples that to in the with a of caused by and sequencing of the point and of and a point mutation of JAK2 in the of PV samples The JAK2 mutation is a G:C→ T:A of Val617 by the we of JAK2 in 20 of 24 samples but not in 12 normal samples the mutation with varying of the mutant JAK2 in the the mutant a of the in in in of the to the The mutation is apparently not to progenitor cells, no in the of mutant JAK2 with cells not the of PV. the point mutation in the of the JAK2 it not the of the of and mutant JAK2 the of the and mutant JAK2 in the samples. the of JAK2 the The mutation point is 14 of the JAK2 is in to a of the and 14 with an in mutation of JAK2 the to mutation with in the to of the mutant the samples. samples that of the JAK2 mutant in the with cDNAs mutant JAK2 with in of is in the mutation of JAK2 in PV in This is not hematopoietic cells and of JAK2 by the mutant cells, the mutant have an to and thus to to the in the the degrees of mutation with cDNAs and that the of JAK2 in PV not but in hematopoietic progenitor of the JAK2 of JAK JAK PubMed Scopus Google Scholar, 6: Scholar). Our of the by the the of in JAK2 The tyrosine kinase domain and pseudokinase domain to the and identified a domain that of the but the domain of JAK2 is not The the domain known the known to PubMed Google Scholar). of the of kinases of 12 with conserved PubMed Scopus Google Scholar, Scholar). The mutation point in of the pseudokinase domain in the The pseudokinase domain has the of but has no that it of the kinase The pseudokinase domain JAK2 by the of the kinase domain but not the inhibitory and have been in the pseudokinase domain PubMed Scopus Google Scholar). Val617 is to the and it is conserved in JAK2 of to It is conserved in human and but is by in that the of by Phe in JAK2 This may the inhibitory of the pseudokinase domain and thus of the kinase have that of the pseudokinase domain to hyperactivation of the with of kinase domain and Blood. PubMed Google Scholar). the of PV disease, it is that may a gain-of-function mutant and have increased kinase JAK2 and of of the gain-of-function of we the tyrosine kinase of JAK2 and the mutant the and mutant in cells by the The cell by to the we used a the of JAK2 the The in that the by a JAK2 and a of that the mutation the kinase of a gain-of-function in cells, we with JAK2 in The cells with and of by of in a of and the of in the of that hyperactivation of signal by EPO, is for the growth of PV progenitor cells and the hypersensitivity of cells to growth factors and cytokines. the we identified an mutation of JAK2 in of PV samples that we This mutation of a by in the pseudokinase domain of JAK2 that has an inhibitory role. gain-of-function Our study by the mutant that the mutant has enhanced kinase and hyperactivation of signal of thus a molecular defect of the PV disease. This have in the and treatment of PV disease. has that tyrosine kinases for drug JAK2 thus a for to is a in by of the EPOR, the receptor and the receptor and the receptor 2002; PubMed Scopus Google Scholar, PubMed Scopus Google Scholar). JAK2 an of to a in PubMed Scopus Google Scholar, PubMed Scopus Google Scholar). This is to in and PubMed Scopus Google that JAK2 has for signal by growth factors and in growth in is Blood. PubMed Google Scholar). EPOR, not kinase activity, but it is with the of to JAK2 and in of and Blood. PubMed Google Scholar). and of progenitor cells the of PV progenitor cells the to in the of (1Green A.R. Lancet. 1996; 347: 844-845Abstract PubMed Scopus (20) Google Scholar, 2Prchal J.F. Prchal J.T. Curr. Opin. Hematol. 1999; 6: 100-109Crossref PubMed Scopus (45) Google Scholar, 3Spivak J.L. Blood. 2002; 100: 4272-4290Crossref PubMed Scopus (369) Google Scholar). have no in in PV cells, suggesting hyperactivation in it is not that we gain-of-function mutation of JAK2 in PV. a possible of JAK2 in PV. The JAK2 is to of of PV and in of PV A.R. PubMed Scopus Google Scholar). we mutation of JAK2 Val617 in 20 of 24 samples a JAK2 mutation of the a JAK have a domain with a kinase domain to a pseudokinase domain PubMed Scopus Google Scholar, 6: Scholar). The domain conserved in The of the in is by the conserved in the in is by in The of the pseudokinase domain has been the pseudokinase domain a by the kinase of The mutation the of in of the pseudokinase may changes and the inhibitory This to the kinase is a clonal disorder and the defect is to the progenitor The hypersensitivity of PV progenitor cells to growth and the growth of of progenitor cells in the of growth factors hyperactivation of an study that PV have Hematol. PubMed Scopus Google and a study increased of in cells PV Hematol. PubMed Scopus Google Scholar). a signal of EPOR, enhanced JAK2 to mutation hyperactivation of cell By JAK2 with in a cell study has that the JAK2 mutant of signal by the JAK2 mutant in hematopoietic progenitor cells normal blood by Blood. PubMed Scopus Google Scholar). to a the growth and of cells in not possible is that gain-of-function mutation of JAK2 not to This that abnormalities of may with PV. have been in A.R. Lancet. PubMed Scopus Google Scholar, PubMed Scopus Google Scholar, J.L. PubMed Scopus Google Scholar, PubMed Scopus Google Scholar). the we identified an mutation of JAK2 in of PV samples that we This mutation of a by in the pseudokinase domain of JAK2 that has an inhibitory role. gain-of-function Our study by the mutant that the mutant has enhanced kinase and hyperactivation of signal of thus a molecular defect of the PV disease. This have in the and treatment of PV disease. has that tyrosine kinases for drug JAK2 thus a for to PV. JAK2 is a in by of the EPOR, the receptor and the receptor and the receptor 2002; PubMed Scopus Google Scholar, PubMed Scopus Google Scholar). JAK2 an of to a in PubMed Scopus Google Scholar, PubMed Scopus Google Scholar). This is to in and PubMed Scopus Google that JAK2 has for signal by growth factors and in growth in is Blood. PubMed Google Scholar). EPOR, not kinase activity, but it is with the of to JAK2 and in of and Blood. PubMed Google Scholar). and of progenitor cells the of PV progenitor cells the to in the of (1Green A.R. Lancet. 1996; 347: 844-845Abstract PubMed Scopus (20) Google Scholar, 2Prchal J.F. Prchal J.T. Curr. Opin. Hematol. 1999; 6: 100-109Crossref PubMed Scopus (45) Google Scholar, 3Spivak J.L. Blood. 2002; 100: 4272-4290Crossref PubMed Scopus (369) Google Scholar). have no in in PV cells, suggesting hyperactivation in it is not that we gain-of-function mutation of JAK2 in PV. a possible of JAK2 in PV. The JAK2 is to of of PV and in of PV A.R. PubMed Scopus Google Scholar). we mutation of JAK2 Val617 in 20 of 24 samples a JAK2 mutation of the a The JAK have a domain with a kinase domain to a pseudokinase domain PubMed Scopus Google Scholar, 6: Scholar). The domain conserved in The of the in is by the conserved in the in is by in The of the pseudokinase domain has been the pseudokinase domain a by the kinase of The mutation the of in of the pseudokinase may changes and the inhibitory This to the kinase PV is a clonal disorder and the defect is to the progenitor The hypersensitivity of PV progenitor cells to growth and the growth of of progenitor cells in the of growth factors hyperactivation of an study that PV have Hematol. PubMed Scopus Google and a study increased of in cells PV Hematol. PubMed Scopus Google Scholar). a signal of EPOR, enhanced JAK2 to mutation hyperactivation of cell By JAK2 with in a cell study has that the JAK2 mutant of signal by the JAK2 mutant in hematopoietic progenitor cells normal blood by Blood. PubMed Scopus Google Scholar). to a the growth and of cells in not possible is that gain-of-function mutation of JAK2 not to This that abnormalities of may with PV. have been in A.R. Lancet. PubMed Scopus Google Scholar, PubMed Scopus Google Scholar, J.L. PubMed Scopus Google Scholar, PubMed Scopus Google Scholar).
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: